• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports Second Quarter 2024 Results

    7/23/24 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 29, 2024.

    Key Financial & Operating Results

    • Second quarter net sales were $213 million versus $238 million during Q2 2023.
    • Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023.
    • Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00).

    Q2 2024 Financial Performance

    Consolidated Results

    Net Sales

    $213 million

    • -11% vs. Q2 2023

     

     

    • -8% constant currency vs. Q2 2023

     

     

    • -7% sequentially

     

     

    • -6% constant currency sequentially

     

     

    • -$5 million YOY FX impact, or -2%

    Diluted EPS

    $0.54

    • -39% vs. Q2 2023

     

     

    • -37% sequentially

    Active Customers

    468,000

    • -4% vs. Q2 2023

     

     

    • -5% sequentially

    "Second quarter operating results were below our expectations," said Jim Brown, President and Chief Executive Officer.

    "Ongoing macroeconomic pressures in several of our key markets continue to impact consumer spending. This in turn creates challenges in our ability to attract and engage new customers and generate sales momentum. To counter these challenges, we have made several strategic changes in our business over the past few quarters, including (i) restructuring our commercial team, (ii) heightening our focus on product innovation, (iii) increasing our efforts to engage our sales leaders with an Associate-first approach, (iv) expanding into India, and (v) evaluating more business development activities.

    "Next month, we will be hosting our Americas & Europe Convention in Las Vegas, Nevada along with other Associate engagement-focused events in the back half of the year. We are also planning to offer a more robust promotional calendar throughout the remainder of the year."

    Q2 2024 Regional Results:

    Asia Pacific Region

    Net Sales

    $171 million

    • -12% vs. Q2 2023

     

     

    • -9% constant currency vs. Q2 2023

     

     

    • -8% sequentially

     

     

    • 80% of consolidated net sales

    Active Customers

    369,000

    • -4% vs. Q2 2023

     

     

    • -7% sequentially

    Asia Pacific Sub-Regions

    Greater China

    Net Sales

    $116 million

    • -10% vs. Q2 2023

     

     

    • -8% constant currency vs. Q2 2023

     

     

    • -9% sequentially

    Active Customers

    250,000

    • Flat vs. Q2 2023

     

     

    • -9% sequentially

    North Asia

    Net Sales

    $20 million

    • -23% vs. Q2 2023

     

     

    • -19% constant currency vs. Q2 2023

     

     

    • -8% sequentially

    Active Customers

    42,000

    • -18% vs. Q2 2023

     

     

    • -7% sequentially

    Southeast Asia Pacific

    Net Sales

    $35 million

    • -10% vs. Q2 2023

     

     

    • -7% constant currency vs. Q2 2023

     

     

    • -2% sequentially

    Active Customers

    77,000

    • -6% vs. Q2 2023

     

     

    • +1% sequentially

    Americas and Europe Region

    Net Sales

    $42 million

    • -5% vs. Q2 2023

     

     

    • -5% constant currency vs. Q2 2023

     

     

    • -1% sequentially

     

     

    • 20% of consolidated net sales

    Active Customers

    99,000

    • -4% vs. Q2 2023

     

     

    • Flat sequentially

    Balance Sheet and Share Repurchase Activity

    The Company generated $8 million in operating cash flow during second quarter and ended the quarter with $332 million in cash and cash equivalents while remaining debt-free. The Company did not repurchase any shares during the quarter. As of June 29, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

    Fiscal Year 2024 Outlook

    The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows:

    Fiscal Year 2024 Outlook

     

    Revised Range

    Previous Range

    Consolidated Net Sales

    $850 - $880 million

    $850 - $920 million

    Diluted EPS

    $2.40 - $2.55

    $2.40 - $3.00

    "While we anticipated lower sequential operating results following a successful promotional period in the first quarter, lower than anticipated active customer counts negatively impacted our second quarter results," said Doug Hekking, Chief Financial Officer. "Additionally, the strengthening of the U.S. dollar created downward pressure on both net sales and operating margin during the quarter."

    Mr. Hekking continued, "We are revising our fiscal 2024 outlook to reflect year-to-date operating results, our expectation for a continued challenging operating environment across many of our markets, higher than anticipated unfavorable currency exchange rate impact on operating results, and an increased effective tax rate. We recognize the need to continue investing in strategic initiatives while also aligning costs with sales performance. Our balance sheet remains strong with $332 million of cash, zero debt, and we continue to generate solid cash flow."

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, July 24, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Non-GAAP Financial Measures

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Quarter Ended

     

    June 29,

    2024

    July 1,

    2023

    Net sales

    $

    212,869

     

    $

    238,202

     

    Cost of sales

     

    40,333

     

     

    43,326

     

    Gross profit

     

    172,536

     

     

    194,876

     

    Operating expenses:

     

     

    Associate incentives

     

    90,371

     

     

    102,380

     

    Selling, general and administrative

     

    64,325

     

     

    68,096

     

    Total operating expenses

     

    154,696

     

     

    170,476

     

    Earnings from operations

     

    17,840

     

     

    24,400

     

    Other income (expense):

     

     

    Interest income

     

    2,763

     

     

    2,224

     

    Interest expense

     

    (51

    )

     

    (43

    )

    Other, net

     

    (349

    )

     

    229

     

    Other income (expense), net

     

    2,363

     

     

    2,410

     

    Earnings before income taxes

     

    20,203

     

     

    26,810

     

    Income taxes

     

    9,771

     

     

    9,518

     

    Net earnings

    $

    10,432

     

    $

    17,292

     

     

     

     

    Earnings per common share

     

     

    Basic

    $

    0.55

     

    $

    0.89

     

    Diluted

    $

    0.54

     

    $

    0.89

     

     

     

     

    Weighted average common shares outstanding

     

     

    Basic

     

    19,073

     

     

    19,321

     

    Diluted

     

    19,159

     

     

    19,427

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    June 29,

    2024

     

    As of

    December 30,

    2023

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    332,423

     

    $

    330,420

    Inventories

     

    61,832

     

     

    61,454

    Prepaid expenses and other current assets

     

    24,826

     

     

    25,872

    Total current assets

     

    419,081

     

     

    417,746

    Property and equipment, net

     

    97,686

     

     

    99,814

    Goodwill

     

    16,837

     

     

    17,102

    Intangible assets, net

     

    28,637

     

     

    29,919

    Deferred tax assets

     

    18,190

     

     

    13,284

    Other assets*

     

    50,988

     

     

    54,892

    Total assets

    $

    631,419

     

    $

    632,757

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    6,648

     

    $

    10,070

    Line of credit - short term

     

    —

     

     

    786

    Other current liabilities

     

    97,248

     

     

    107,989

    Total current liabilities

     

    103,896

     

     

    118,845

    Deferred tax liabilities

     

    4,653

     

     

    4,552

    Other long-term liabilities

     

    10,662

     

     

    12,158

     

     

     

     

    Stockholders' equity

     

    512,208

     

     

    497,202

    Total liabilities and stockholders' equity

    $

    631,419

     

    $

    632,757

    *Other assets include noncurrent inventories of $3,075 and $3,128 as of 29-Jun-24 and 30-Dec-23, respectively. Total inventories were $64,907 and $64,582 as of 29-Jun-24 and 30-Dec-23, respectively.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter Ended

     

    Change from

    prior

    year

     

    Percent

    change

     

    Currency

    impact on

    sales

     

    % change

    excluding

    currency

    impact

     

    June 29, 2024

     

    July 1, 2023

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Greater China

    $

    115,513

     

    54.3

    %

     

    $

    128,749

     

    54.1

    %

     

    $

    (13,236

    )

     

    (10.3

    %)

     

    $

    (3,085

    )

     

    (7.9

    %)

    Southeast Asia Pacific

     

    35,402

     

    16.6

    %

     

    $

    39,337

     

    16.5

    %

     

     

    (3,935

    )

     

    (10.0

    %)

     

     

    (1,221

    )

     

    (6.9

    %)

    North Asia

     

    19,710

     

    9.3

    %

     

    $

    25,529

     

    10.7

    %

     

     

    (5,819

    )

     

    (22.8

    %)

     

     

    (870

    )

     

    (19.4

    %)

    Asia Pacific Total

     

    170,625

     

    80.2

    %

     

     

    193,615

     

    81.3

    %

     

     

    (22,990

    )

     

    (11.9

    %)

     

     

    (5,176

    )

     

    (9.2

    %)

    Americas and Europe

     

    42,244

     

    19.8

    %

     

     

    44,587

     

    18.7

    %

     

     

    (2,343

    )

     

    (5.3

    %)

     

     

    (94

    )

     

    (5.0

    %)

     

    $

    212,869

     

    100.0

    %

     

    $

    238,202

     

    100.0

    %

     

    $

    (25,333

    )

     

    (10.6

    %)

     

    $

    (5,270

    )

     

    (8.4

    %)

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

    Active Associates by Region(1)

    (unaudited)

     

    As of

    June 29, 2024

     

    As of

    July 1, 2023

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    68,000

     

    35.2

    %

     

    71,000

     

    34.1

    %

    Southeast Asia Pacific

    52,000

     

    27.0

    %

     

    57,000

     

    27.4

    %

    North Asia

    28,000

     

    14.5

    %

     

    33,000

     

    15.9

    %

    Asia Pacific Total

    148,000

     

    76.7

    %

     

    161,000

     

    77.4

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    45,000

     

    23.3

    %

     

    47,000

     

    22.6

    %

     

    193,000

     

    100.0

    %

     

    208,000

     

    100.0

    %

     

    Active Preferred Customers by Region(2)

    (unaudited)

     

    As of

    June 29, 2024

     

    As of

    July 1, 2023

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    182,000

     

    66.2

    %

     

    180,000

     

    64.5

    %

    Southeast Asia Pacific

    25,000

     

    9.1

    %

     

    25,000

     

    9.0

    %

    North Asia

    14,000

     

    5.1

    %

     

    18,000

     

    6.4

    %

    Asia Pacific Total

    221,000

     

    80.4

    %

     

    223,000

     

    79.9

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    54,000

     

    19.6

    %

     

    56,000

     

    20.1

    %

     

    275,000

     

    100.0

    %

     

    279,000

     

    100.0

    %

    (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240723833865/en/

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INFORMATION OFFICER Benedict Peter converted options into 2,788 shares and covered exercise/tax liability with 967 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:56:37 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF OPERATING OFFICER Noot Walter covered exercise/tax liability with 4,160 shares and converted options into 9,138 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:55:30 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF COMMERCIAL OFFICER Neidig Brent converted options into 7,310 shares and covered exercise/tax liability with 3,551 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:54:18 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    Amendment: USANA Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    2/11/26 4:51:10 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

    SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    1/21/26 1:21:12 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    1/12/26 6:29:11 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps

    SALT LAKE CITY, Feb. 2, 2026 /PRNewswire/ -- As organizations face rapid market disruption and evolving leadership demands, Feb. 2 marks Self-Renewal Day, a pivotal time for business leaders to recalibrate strategies and personal development. "Growth does not happen by accident; it happens by choice," said  Kevin Guest, Executive Chairman & CEO at USANA Health Sciences (NYSE:USNA). "Self-Renewal Day is designed to prompt people to evaluate their lives, challenge complacency, and take deliberate steps toward personal and professional renewal." This annual observance is a critic

    2/2/26 7:05:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings

    ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Baystreet.ca News Commentary  VANCOUVER, BC, Jan. 19, 2026 /PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE:PM), Celsius Holdings (NASDAQ:CELH), USANA Health Sciences (NYSE:USNA), and Medifast (NYSE:MED

    1/19/26 12:10:00 PM ET
    $CELH
    $MED
    $PM
    Beverages (Production/Distribution)
    Consumer Staples
    Packaged Foods
    Medicinal Chemicals and Botanical Products

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow

    10/20/25 5:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care